Comparative Pharmacology
Head-to-head clinical analysis: ANSPOR versus CEFOTETAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANSPOR versus CEFOTETAN.
ANSPOR vs CEFOTETAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
250-500 mg orally every 6 hours for 10-14 days; maximum 4 g/day.
1 to 2 g intravenously or intramuscularly every 12 hours. For severe infections, up to 2 g every 12 hours for 5-10 days.
None Documented
None Documented
1.5–2 hours in adults with normal renal function; prolonged to 20–30 hours in severe renal impairment (CrCl <10 mL/min)
3-4.5 hours (6-8 hours in renal impairment).
Primarily renal (90–95%) as unchanged drug via glomerular filtration and tubular secretion; biliary excretion negligible (<1%)
Renal (80-90% unchanged), biliary (small amount, up to 20% in bile), fecal (<5%).
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic